Reprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer
A very strong Mount Sinai / Cell Reports Medicine -CRC paper says it again:
According to the study the combination therapy achieved up to 100 percent tumor clearance in models of mismatch repair-deficient colorectal cancer, and more than 70 percent clearance in mismatch repair-proficient tumors, which are typically resistant to immunotherapy.
“This approach effectively reprograms the tumor microenvironment,” said first author Guillaume Mestrallet, PhD, a postdoctoral fellow in the Bhardwaj Lab at Mount Sinai. “By simultaneously reinvigorating T cells and targeting suppressive macrophages, we were able to restore immune coordination and generate powerful anti-tumor responses.”
Importantly, the study also demonstrated the development of immune memory, suggesting the potential for long-lasting protection against cancer recurrence. The findings have significant implications for the future of cancer treatment, supporting the development of rational combination immunotherapies that go beyond single-agent approaches
Very close to the biological logic that Bex is also based on.